Candel Therapeutics — Third Quarter 2026 Earnings Summary

Candel Therapeutics reported a net loss of $21.9 million for the third quarter of 2026, driven by increased research and development expenses related to clinical trials and manufacturing. The company holds $203.1 million in cash and cash equivalents as of September 30, 2026, which is projected to fund operations through the second quarter of 2028. Clinical updates include the acceptance of three poster presentations at the SITC 2026 Annual Meeting and the announcement of a planned Biologics License Application submission for aglatimagene in prostate cancer in mid-2027. Recent corporate developments include the appointment of Martine Zimmermann to the Board of Directors and Maria Ostrovsky as General Counsel to support regulatory and commercial readiness.